Keryx Biopharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
February 06 2014 - 8:30AM
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that
Ron Bentsur, the Company's Chief Executive Officer, will be
presenting at the 16th Annual BIO CEO & Investor Conference, to
be held February 10-11, 2014, at the Waldorf Astoria Hotel in New
York City. Mr. Bentsur's presentation will take place on Monday,
February 10th, at 4:00pm ET.
A live audio webcast of Mr. Bentsur's presentation will be
accessible within the Investor Relations section of the Company's
website at http://www.keryx.com/webcasts-presentations. An archived
version of this webcast will be available following the conclusion
of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition,
development and commercialization of medically important
pharmaceutical products for the treatment of renal disease. Keryx
is developing ZerenexTM (ferric citrate coordination complex), an
oral, ferric iron-based compound. Zerenex has completed a
U.S.-based Phase 3 clinical program for the treatment of
hyperphosphatemia (elevated phosphate levels) in patients with
chronic kidney disease on dialysis, conducted pursuant to a Special
Protocol Assessment ("SPA") agreement with the FDA. Keryx's New
Drug Application ("NDA"), submitted to the FDA in 2013, is
currently under review and has an assigned Prescription Drug User
Fee Act ("PDUFA") goal date of June 7, 2014. Zerenex has also
completed a Phase 2 study in the U.S. for the management of
elevated serum phosphorus levels and iron deficiency anemia in
patients with Stage 3 to 5 non-dialysis dependent chronic kidney
disease. Top-line results from this Phase 2 study were
announced in November 2013. In addition, Keryx's Japanese
partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd.,
received marketing approval of ferric citrate in Japan for the
treatment of hyperphosphatemia in patients with chronic kidney
disease on January 17, 2014. Keryx is headquartered in New
York City.
CONTACT: KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024